Birds of a feather…

Some of you may have been following the news about venture capitalist Martin Shkreli who decided

to raise the price of toxoplasmosis drug Daraprim from $13.50 a pill to $750.

Mr. Shkreli has gone on to enrage basically everybody by defending his moves on social media and traditional media with, shall we say, aplomb.

Then one of the scitweeps remembered something interesting:

.@MHendr1cks He's the dude that funded Perlstein's lab!

— boehninglab (@boehninglab) September 22, 2015

What?

Yep.

Of the $2 million seed money, New York-based Retrophin and the Wilsey family foundation in San Francisco have combined to contribute about one-third. The rest has come from angel funders in increments of $10,000 to $400,000, Perlstein says.

Perlstein first caught Retrophin CEO Martin Shkreli’s attention on Twitter, and their exchange led to a meeting at the J.P. Morgan conference in San Francisco.

@MartinShkreli cool, thanks! As I plow ahead with Perlstein Lab, I'll be watching Retrophin with great interest (and Ultragenyx, too)

— Ethan Perlstein (@eperlste) January 2, 2014

https://twitter.com/MartinShkreli/status/418603162971287554

Sounds like the start of a beautiful relationship.